ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).

Detailed Description
-----------------
This protocol is designed to test the safety and efficacy of a drug called Beloranib (ZGN-440). It is to be tested for its ability to reduce weight in obese female subjects who are of non-childbearing potential. The study will provide information on how much ZGN-440 gets into the blood, how long it stays in the body, and how it affects other biological markers.

Official Title
-----------------
ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Initial Weight Loss

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Drug: ZGN-440
* Drug: ZGN-440 sterile diluent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obese but otherwise healthy females Non-childbearing potential (surgically sterile, post-menopausal, or receiving implanted or injectable contraceptive for at least 3 months) BMI ≥ 30 and ≤ 45 kg/m2 Stable body weight during the past 2 months Exclusion Criteria: Use of weight loss agents in the past month History of eating disorder History of type 1 or type 2 diabetes mellitus Current smokers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: ZGN-440 sterile diluent<br> | Drug: ZGN-440 sterile diluent<br>* Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.<br>|
| Experimental: ZGN-440<br> | Drug: ZGN-440<br>* Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.<br>* Other names: Beloranib for subcutaneous injection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demonstrate safe doses of ZGN-440 for reduction of body weight in obese female volunteers. | Measures of the safety and tolerability of ZGN-440 include documentation of adverse events and changes (compared to baseline) in vital signs, physical examination, heart rhythm, and laboratory tests. | Approximately 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence, severity and dose-relationship of adverse events as well as changes in physical examinations, ECGs, vital signs and/or laboratory evaluations as a measure of safety and tolerability. |  | Approximately 4 weeks | 
| Peak plasma concentration of ZGN-440 to assess relationship to weight loss. |  | Approximately 4 weeks | 
| Elimination half-life of ZGN-440 to assess relationship to weight loss. |  | Approximately 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obese, Obesity, Overweight